Standout Papers

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study 2023 2026 2024199
  1. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023)
    Silvia Novello, Dariusz M. Kowalski et al. Journal of Clinical Oncology

Immediate Impact

69 standout
Sub-graph 1 of 22

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
The cancer-immunity cycle: Indication, genotype, and immunotype
2023 Standout
1 intermediate paper

Works of Alexander Golf being referenced

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
2023 Standout

Author Peers

Author Last Decade Papers Cites
Alexander Golf 309 181 61 13 342
Deepa Rangachari 295 174 49 13 348
Ilze Bāra 253 220 36 22 353
Cindy Yun 269 165 91 13 317
Giuseppe Giaccone 289 155 27 17 388
Longgang Cui 290 157 69 15 369
X. Tchiknavorian 266 148 96 13 358
Jiewen Peng 205 100 57 18 327
Shiang Jiin Leaw 298 199 19 10 369
Christopher Dakhil 255 190 125 20 374
Gui‐Nan Lin 252 95 129 9 352

All Works

Loading papers...

Rankless by CCL
2026